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Multiple system atrophy (MSA) is an adult-onset, sporadic neurodegenerative disease.
Because the prognosis of MSA is fatal, neuroprotective or regenerative strategies may
be invaluable in MSA treatment. Previously, we obtained clinical and imaging evidence
that mesenchymal stem cell (MSC) treatment could have a neuroprotective role in MSA
patients. In the present study, we evaluated the effects of MSC therapy on longitudinal
changes in subcortical deep graymatter volumes and cortical thickness and their association
with cognitive performance. Clinical and imaging data were obtained from our previous
randomized trial of autologousMSC inMSA patients. During 1-year follow-up, we assessed
longitudinal differences in automatic segmentation-based subcortical deep gray matter
volumes and vertex-wise cortical thickness between placebo (n = 15) and MSC groups
(n = 11). Next, we performed correlation analysis between the changes in cortical thickness
and changes in the Korean version of the Montreal Cognitive Assessment (MoCA) scores
and cognitive performance of each cognitive subdomain using a multiple, comparison
correction. There were no signiﬁcant differences in age at baseline, age at disease onset,
gender ratio, disease duration, clinical severity, MoCA score, or education level between
the groups. The automated subcortical volumetric analysis revealed that the changes in
subcortical deep gray matter volumes of the caudate, putamen, and thalamus did not
differ signiﬁcantly between the groups. The areas of cortical thinning over time in the
placebo group were more extensive, including the frontal, temporal, and parietal areas,
whereas these areas in the MSC group were less extensive. Correlation analysis indicated
that declines in MoCA scores and phonemic ﬂuency during the follow-up period were
signiﬁcantly correlated with cortical thinning of the frontal and posterior temporal areas and
anterior temporal areas inMSApatients, respectively. In contrast, no signiﬁcant correlations
were observed in the MSC group. These results suggest that MSC treatment in patients
with MSA may modulate cortical thinning over time and related cognitive performance,
inferring a future therapeutic candidate for cognitive disorders.
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INTRODUCTION
Multiple system atrophy (MSA) is a sporadic neurodegenerative
disease characterized by α-synuclein-positive glial cytoplasmic
inclusions (GCIs) with widespread neuronal loss in the basal
ganglia, brainstem, cerebellum, and spinal cord. Clinically, the
cardinal features of MSA include autonomic dysfunction, parkin-
sonism, cerebellar ataxia, and pyramidal signs in any combina-
tion, with autonomic dysfunction being an integral component
(Stefanova et al., 2009). In addition, accumulating evidence sug-
gests that along with cortical pathology involving frontal and
temporal areas, cognitive function is more widely impaired in
MSA than initially expected (Kawai et al., 2008; Chang et al.,
2009).
Although the precise etiology and pathomechanisms of MSA
remain unknown, several mediators including neuroinﬂamma-
tion, oxidative insult, mitochondrial dysfunction, and alterations
in the blood–brain barrier have been suggested to play impor-
tant roles in progression of MSA pathology (Shults et al., 2005;
Stefanova et al., 2005; Ubhi et al., 2009; Song et al., 2011b). Many
clinical trials focusing on modulation of MSA pathogenesis have
been conducted to achieve neuroprotective properties; however,
the results have been discouraging (Ubhi et al., 2011). In a
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randomized, double-blind, controlled trial of autologous mes-
enchymal stem cells (MSC), we obtained clinical and imaging
evidence that MSC treatment could have a neuroprotective role in
MSA patients (Lee et al., 2012b). In the present study, we evaluated
the effects of MSC therapy on longitudinal changes in subcortical
deep gray matter volumes and cortical thickness and their associa-
tion with cognitive performance to elucidate whether MSC could
modulate pathological processes in the cerebral cortex of MSA
patients.
MATERIALS AND METHODS
SUBJECTS
Clinical and imaging data were obtained from our random-
ized trial of autologous MSC that was reported previously
(Lee et al., 2012b). Brieﬂy, patients with probable MSA-
cerebellar type (Gilman et al., 1999) and baseline Uniﬁed Mul-
tiple System Atrophy Rating Scale (UMSARS, scores rang-
ing from 0 to 106, with higher scores indicating greater
neurological deﬁcits) (Wenning et al., 2004) scores of 30–50
were enrolled in this study. Because functional deterioration
in MSA is known to be more rapid in early stages than
in advanced stages of the disease (Geser et al., 2006), we
recruited MSA patients with mild-to-moderate stages of the
disease with the expectation that early intervention would be
more appropriate to achieve clinical efﬁcacy. The subjects
were randomly assigned to the MSC group receiving MSC
(4 × 107/injection) via intra-arterial and intravenous routes
or placebo group. The detailed neuropsychological test and
brain magnetic resonance imaging (MRI) were performed at
baseline and at 12 months after ﬁrst intra-arterial adminis-
tration of MSC. All patients provided written informed con-
sent. The trial was registered at ClinicalTrials.gov (Clinical-
Trials.gov number NCT00911365), and the study protocol
and consent form were approved by the Institutional Review
Board for Human Investigation of Yonsei University Severance
Hospital.
IMAGE ACQUISITION
All MRI scans of patients were acquired using a Philips 3.0T
scanner (Philips Intera, Philips Medical System, Best, The Nether-
lands) with a SENSE head coil (SENSE factor = 2). Head motion
was minimized with restraining foam pads provided by the man-
ufacturer. A high-resolution, T1-weighted MRI volume dataset
was obtained using 3-dimensional T1-TFE sequence conﬁgured
with the following acquisition parameters: axial acquisition with a
224 × 256matrix; 256 × 256 reconstructedmatrix with 182 slices;
220mmﬁeld of view; 0.98 mm × 0.98mm × 1.2 mm voxels; echo
time 4.6 msec; repetition time 9.6 msec; ﬂip angle 8◦; slice gap
0 mm.
CORTICAL THICKNESS ANALYSIS
Native MR images were registered into a standardized, stereotac-
tic space using linear transformation (Collins et al., 1994). The
N3 algorithm was used to correct images for intensity-based non-
uniformities, resulting from inhomogeneity in the magnetic ﬁeld
(Sled et al., 1998). The non-brain tissues were removed from regis-
tered and corrected volumes (Smith, 2002) and then classiﬁed into
white matter, gray matter, cerebrospinal ﬂuid (CSF), and back-
ground using the Intensity-Normalized Stereotactic Environment
for Classiﬁcation of Tissues algorithm (Zijdenbos et al., 1996).
The surfaces of the inner and outer cortices which consisted of
40,962 verticeswere automatically extracted using theConstrained
Laplacian-based Automated Segmentation with Proximities algo-
rithmand inversely transformed to native space (MacDonald et al.,
2000; Kim et al., 2005). In inner surface, a low-resolution, poly-
hedral surface deformed to ﬁt the gray matter and white matter
boundary and resampled to contain 81,920 polygons. Then, the
outer cortical surface is expanded from inner surface using a Lapla-
cian map deﬁned between white matter and cerebrospinal ﬂuid.
The each vertex of inner and outer surfaces had the correspon-
dence. Thus, the cortical thickness was deﬁned as the Euclidean
distance between linked vertices of the inner and outer native sur-
faces, because Lerch and Evans (2005) considered this method
of cortical thickness measurement to be the simplest and most
precise of several methods. The cortical thickness information
was smoothed with 20 mm full-width half-maximum Gaussian
smoothing kernel to increase the signal-to-noise ratio (Lerch and
Evans, 2005; Im et al., 2006) and aligned to unbiased iterative
surface template using vertex-wise, sphere-to-sphere, non-linear
surface registration (Robbins et al., 2004; Lyttelton et al., 2007).
SEGMENTATION AND VOLUMETRIC ANALYSIS FOR SUBCORTICAL
STRUCTURE
Volume of subcortical structures was analyzed by using FMRIB’s
Softward Library-FMRIB’s Integrated Registration and Segmen-
tation Tool (FIRST, version 5.0). The method is the auto-
mated, model-based tool, which is optimized for registra-
tion and segmentation of deep subcortical structures including
caudate, putamen, pallidum, and thalamus (Patenaude et al.,
2011). The T1-weighted MR inputs are registered to Mon-
treal Neurological Institute 152 standard space with 12 DOF
(degree of freedom) afﬁne transformation. Second, based on
shape sample using another 12 DOF registration with appli-
cation of subcortical mask, each structure was segmented.
Then, boundary correction was performed with FSL’s FAST
tool, which re-classiﬁes boundary voxels to each subcortical
structure in accordance with their intensity. Finally, summary
of segmented volumes of bilateral caudate, pallidum and tha-
lamus was acquired using routine FSL command: FSLstats
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Fslutils).
NEUROPSYCHOLOGICAL TESTS
To evaluate the changes in general cognition for follow-up
period, the Korean version of the Montreal Cognitive Assess-
ment (MoCA) was introduced in both groups of MSA patients.
In addition, we used the Seoul Neuropsychological Screening
Battery (SNSB) to determine the cognitive performance in both
groups of patients (Kang and Na, 2003; Song et al., 2011a).
The SNSB covers attention, language, praxis, visuoconstruc-
tive function, verbal and visual memory, and frontal/executive
function. For these, the quantiﬁable tests comprised the digit
span (forward and backward), Korean version of the Boston
Naming Test, Rey Complex Figure Test (copying, immedi-
ate and 20-min delayed recall, and recognition), Seoul Verbal
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Learning Test (three learning-free recall trials of 12 words, 20-
min delayed recall trial for these 12 items, and a recognition
test), phonemic and semantic Controlled Oral Word Associa-
tion Test, go-no-go test and contrasting program, and Stroop
Test (word and color reading of 112 items during a 2-min
period).
STATISTICAL ANALYSIS
To assess longitudinal differences of cortical thickness in each
group, we performed a random ﬁeld theory using Surfstat pack-
age (http://www.math.mcgill.ca/keith/surfstat). In each MSC and
placebo group, a longitudinal difference was tested by a general
linear model at vertex-wise cortical thickness with controlling for
gender and age at baseline characteristics. Multiple comparisons
were taken into account for the vertex-wise test using a false dis-
covery rate (FDR; Genovese et al., 2002) correction at a 0.05 level
of signiﬁcance. Next, the correlations of longitudinal changes of
cortical thickness and cognitive performance were explored using
a multiple, linear regression model in each group. We constructed
the regression model accounting with gender and age as inde-
pendent variables. Initially, we obtained the longitudinal changes
of cortical thickness and cognitive scores over 12 months. Then,
the multiple, linear regressions between the differences of cortical
thickness and cognitive scores were performed in entire vertices
and p value of 0.05 was assigned to correlation map using an FDR
correction. To compare demographic data and changes in sub-
cortical gray matter volumes between groups, the Fisher’s exact
test and Mann–Whitney U test were used for categorical and
continuous variables, respectively. The changes of mean corti-
cal thickness in each group were assessed using Wilcoxon signed
rank test. Additionally, Spearman’s correlation analysis was used
to evaluate the relationship between the changes in subcorti-
cal gray matter volumes and cognitive performance. Statistical
analyses were performed using commercially available software
(SPSS, version 18.0), and a two-tailed p < 0.05 was considered
signiﬁcant.
RESULTS
DEMOGRAPHIC CHARACTERISTICS
Baseline and follow-up brain MRI data were available for 11
patients in the MSC group and 15 patients in the placebo group.
The demographic characteristics are shown in Table 1. There were
no signiﬁcant differences in age at baseline, age at disease onset,
gender ratio, disease duration, UMSARS score, Mini-Mental Sta-
tus Examination (MMSE) score, MoCA score, or education level
between the groups.
CHANGES IN SUBCORTICAL DEEP GRAY MATTER VOLUMES AND
RELATED COGNITIVE PERFORMANCE
The changes in subcortical deep gray matter volumes assessed
by a computerized segmentation procedure are shown in
Table 2. The volumes of deep gray matter including the
caudate, putamen, pallidum, and thalamus were decreased
at day 360 relative to baseline in both groups; however,
the changes subcortical volumes did not differ signiﬁcantly
between the placebo and MSC groups. In a correlation anal-
ysis, the changes in subcortical gray matter volumes did not
Table 1 | Baseline characteristics of the study subjects.
Characteristics Placebo MSC p value
No. of subjects 15 11
Age (year) 55.8 ± 6.3 56.7 ± 8.9 0.77
Sex (female, %) 5 ± 33.3 5 ± 45.5 0.69
Disease duration (months) 33.0 ± 16.7 41.0 ± 13.5 0.25
Total UMSARS score 38.6 ± 6.3 39.2 ± 8.9 0.84
MMSE 27.3 ± 2.5 27.1 ± 2.3 0.88
MoCA 24.1 ± 3.9 24.7 ± 2.9 0.66
Education duration (year) 11.8 ± 4.7 11.7 ± 5.2 0.98
Cortical thickness (mm) 3.20 ± 0.09 3.13 ± 0.12 0.21
Data are mean ± SD. MSC, mesenchymal stem cells; UMSARS, Uniﬁed Multiple
System Atrophy Rating Scale; MMSE, Mini-Mental Status Examination; MoCA,
Montreal Cognitive Assessment.
Table 2 | Changes in subcortical deep gray matter volumes between
the placebo and MSC groups.
Placebo (mm3) MSC (mm3) p value
Left caudate nucleus 169.87 ± 357.07 175.2 ± 194.7 0.88
Right caudate nucleus 132.32 ± 216.76 117.96 ± 85.17 0.94
Left putamen 378.31 ± 216.43 359.57 ± 227.03 0.99
Right putamen 378.20 ± 210.94 430.04 ± 272.34 0.87
Left pallidum 77.28 ± 105.65 127.31 ± 114.61 0.28
Right pallidum 123.93 ± 151.04 120.90 ± 54.06 0.70
Left thalamus 404.35 ± 237.57 364.51 ± 106.99 0.64
Right thalamus 322.58 ± 241.15 362.63 ± 124.63 0.59
Data are mean ± SD. MSC, mesenchymal stem cells.
show a signiﬁcant correlation with the changes of MoCA
score or cognitive performance of speciﬁc subdomains in both
groups.
CHANGES IN CORTICAL THICKNESS AND RELATED COGNITIVE
PERFORMANCE
The baseline mean cortical thickness in the placebo and MSC
groups was 3.20 ± 0.09 and 3.13 ± 0.12 mm, respectively. The
change of mean cortical thickness during the follow-up period
was 0.097 mm in the placebo group (p = 0.005) and 0.069 mm in
the MSC group (p = 0.012). In comparison to changes in cortical
thickness during the follow-up period, the areas of cortical thin-
ning in the placebo group at day 360 compared with the baseline
were more extensive, including the frontal, temporal, and pari-
etal areas, whereas cortical thinning in the MSC group during the
follow-up period was less extensive and localized mainly to the
frontal area (Figure 1).
Both baseline and follow-up neuropsychological data were
available for 10 patients in the MSC group and 15 patients in
the placebo group, and the changes in cognitive performance of
speciﬁc subdomains in each group were reported previously (Lee
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et al., 2012b). Brieﬂy, the placebo group exhibited a signiﬁcantly
worsening performance in general cognition, forward digit span,
naming, visuospatial function, visual and verbal memory, and
frontal executive function, whereas theMSC group showed no sig-
niﬁcant deterioration of cognitive performance, except in Stroop
color score. In a correlation analysis of longitudinal changes in
cortical thinning and general cognition, the placebo group had
signiﬁcant clusters in which the changes in MoCA scores were
signiﬁcantly and positively correlated with the changes in corti-
cal thickness in the left prefrontal and superior temporal areas
(Figure 2). In contrast, the MSC group showed no signiﬁcant
correlations between longitudinal changes in MoCA score and
cortical thickness. In analyzing the correlations of changes in cor-
tical thickness and each cognitive subdomain performance, only
the change in phonemic ﬂuency was signiﬁcantly and positively
correlated with cortical thinning in the left anterior temporal
area in the placebo group. In contrast, the MSC group had no
signiﬁcant clusters in which changes in cortical thickness were sig-
niﬁcantly correlated with change in cognitive subdomain scores
(Figure 3).
DISCUSSION
The present study demonstrated that cortical thinning over time,
as a primary disease process, is closely associated with cognitive
decline in patients with MSA over time. Furthermore, MSC treat-
ment in patients withMSAmaymodulate longitudinal changes in
cortical thickness and its related decline in cognitive performance,
suggesting that MSC may have a future therapeutic potential for
primary cognitive disorders.
Although dementia is one of the exclusion criteria for the
diagnosis of MSA (Gilman et al., 1999), there is evidence that a
large portion of MSA patients exhibit a wider range of cognitive
dysfunctions than bas been considered (Burk et al., 2006; Kawai
et al., 2008; Chang et al., 2009; Brown et al., 2010). With regard to
the anatomical substrate of cognitive dysfunction, pathological
changes in the striatum and cerebellum can inﬂuence cogni-
tive performance in MSA because the cerebellum as well as the
striatumcontributes to cognitive tasks of frontal executive and lan-
guage functions and visuospatial performance (Burk et al., 2006;
Kawai et al., 2008). In addition, recent pathological and imaging
studies have demonstrated widespread cortical involvement in
FIGURE 1 | Longitudinal changes in cortical thickness in both groups.The areas of cortical thinning in the placebo group during the follow-up period were
more extensive, including the frontal, temporal, and parietal areas, whereas cortical thinning over time in the mesenchymal stem cell (MSC) group was less
extensive.
FIGURE 2 | Correlation analysis of longitudinal changes in cortical
thinning and general cognition. In patients with multiple system
atrophy (MSA) receiving placebo, declines in MoCA scores and during the
follow-up period were signiﬁcantly correlated with cortical thinning of the
frontal and posterior temporal areas. However, the mesenchymal stem
cell (MSC) group had no signiﬁcant clusters in which the changes in
MoCA scores were signiﬁcantly correlated with the changes in cortical
thickness.
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FIGURE 3 | Correlation analysis of longitudinal changes in cortical thinning and cognitive subdomain scores. Decrease in phonemic ﬂuency was
signiﬁcantly correlated with cortical thinning in the left anterior temporal area in the placebo group; however, no signiﬁcant correlations were observed in the
mesenchymal stem cell (MSC) group.
MSA pathology, which may function as a key contributor to cog-
nitive dysfunctions in MSA. Papp and Lantos (1994) reported
selective GCI pathology in the primary sensorimotor, supple-
mentary motor, and anterior cingulate cortices in MSA patients.
Konagaya et al. (1999) reported a mildly demented MSA patient
with prominent frontal atrophy and pronounced GCI distribu-
tion in themotor area of the frontal lobe and the parietal lobe. In a
voxel-based morphometric study, Brenneis et al. (2006) reported
reduced gray matter density in the orbitofrontal, dorsolateral,
and medial frontal, parietal, and insular areas, and Lyoo et al.
(2008) showed that frontal hypometabolism occurred in the early
stages of MSA-cerebellar type. These data suggest that cortical
pathology may act as a key contributor to cognitive dysfunction
in MSA.
In the present study, we demonstrated longitudinal changes in
cortical thickness and its correlation with cognitive performance.
In patients with MSA receiving placebo treatment, the areas of
cortical thinning during a 1-year follow-up period were exten-
sively widespread throughout the whole cortical area, maximally
involving the frontal and temporal areas. These areas show good
accordance with the decline in cognitive subdomains of atten-
tion, memory, visuospatial function, and executive function in
MSA patients receiving placebo. Interestingly, changes in general
cognition during follow-up assessed by MoCA were signiﬁcantly
correlated with cortical thinning of the frontal and posterior
temporal areas in MSA patients. Furthermore, in analyzing the
correlation of changes in speciﬁc cognitive subdomains and cor-
tical thinning, decline in phonemic ﬂuency during the follow-up
period was signiﬁcantly correlated with cortical thinning of the
anterior temporal area in MSA patients. On the other hand, the
changes in subcortical gray matter volumes did not show a signiﬁ-
cant correlation with the changes of general cognition or cognitive
performance of speciﬁc subdomains. Therefore, the present data
suggest that cortical thinning in MSA would be associated with
the primary disease process rather than secondary changes due
to degeneration of cerebello-cortical projections or striatal deaf-
ferentation, and cortical thinning in these areas are responsible for
decline in cognitive performance.
As shown in a previous study indicating that MSC treat-
ment led to signiﬁcant attenuation of the decrease in cerebral
glucose metabolism and gray matter density over time (Lee
et al., 2012b), the present study demonstrated that MSC treat-
ment markedly curtailed areas of cortical thinning over time
relative to placebo treatment, thus providing another imaging
evidence for the neuroprotective effects of MSC with higher sta-
tistical power. In addition, in contrast to the placebo group,
longitudinal changes in cortical thickness did not show signiﬁ-
cant correlations with changes in general cognitive performance
or speciﬁc subdomain performance in MSA patients receiv-
ing MSC treatment. On the other hand, longitudinal changes
in subcortical deep gray matter volumes did not differ sig-
niﬁcantly between the placebo and MSC groups. According
to our randomized trial, MSC seemed to have neuroprotec-
tive effects in patients with MSA-cerebellar type, thus lead-
ing to a change in the natural clinical course. Similarly, we
postulate that MSC treatment may inﬂuence or modulate nat-
ural progression of cortical MSA pathology, which may lead
to less profound cortical thinning and less decline in cogni-
tive performance over time. As a result, a signiﬁcant correla-
tion between over-time cortical thinning and cognitive decline
is no more evident in MSA patients receiving MSC treat-
ment.
Several studies demonstrated that MSCs can modulate neu-
roprotective properties in animal models of Alzheimer’s disease
(AD). Kim et al. (2012) reported that transplantation of human
MSCs in AD transgenic mice enhanced Aβ clearance through aug-
mentation of neprilysin expression in microglia. Recently, Lee
et al. (2012a) described that a chemoattractive factor secreted
from MSCs may play a critical role in recruitment of alterna-
tive microglia into the AD brain and neprilysin derived from the
alternative microglia may lead to a reduction in Aβ deposition and
memory impairment in AD mice. Furthermore, we very recently
demonstrated themodulatory effect of MSCs on autophagy, a vital
pathway for degradation of abnormal and aggregated proteins in
AD models, showing that MSC treatment signiﬁcantly enhanced
autophagolysosome formation and clearance of Aβ in Aβ-treated
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cellular and AD transgenic mice with an increased neuronal sur-
vival against Aβ toxicity (Shin et al., 2014). Taken together, it
can be inferred that the present data may extend clinical appli-
cation of MSC in primary dementia, such as AD; however, a large
amount of cumulative evidence is required to perform a clinical
trial.
Some limitations of the present study must to be consid-
ered. First, the sample size of the present study was too small
to draw a solid conclusion. Second, we recruited patients with
MSA-cerebellar type only, because like Japanese MSA patients,
MSA-cerebellar type seems tobemoreprevalent inKoreanpatients
relative to MSA-cerebellar type (Watanabe et al., 2002; Seo et al.,
2010). Therefore, our ﬁndings may not apply to patients with
MSA-Parkinsonian type, and a further study is required to val-
idate our ﬁndings. Finally, the present study did not contain
the pathological data, and thus, our results could not provide
direct evidence that MSCmaymodulate cortical MSA pathologies
and related cognitive performance. Accordingly, our data should
be interpreted with caution until pathological data would be
available.
In summary, the present data demonstrated that cortical thin-
ning over time, as a primary disease process, is responsible for
cognitive decline in patients with MSA over time, and MSC treat-
mentmaymodulate longitudinal changes in cortical thickness and
cognitive performance, suggesting future therapeutic potential for
primary dementias.
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